Testicular tumors are rare tumors, accounting for 1% to 1.5% of male tumors, 5% of urinary system tumors, and 3 to 4 new cases per million males per year in Western countries. Over the past 40 years, the incidence of testicular tumors worldwide has increased by more than onefold, with industrialized countries significantly higher than other countries.
The causes of testicular tumors are not yet fully understood. According to epidemiological analysis, there are many risk factors. Among them, congenital factors include cryptorchidism or undescended testicles, familial genetic factors, Klinefelter syndrome, testicular feminization syndrome, polyglandularism, and excessive estrogen secretion. Acquired factors are generally believed to be related to injury, infection, occupational and environmental factors, nutritional factors, and excessive use of exogenous estrogen during pregnancy. Genetic studies have shown that testicular tumors are related to chromosomal translocation on the short arm of chromosome 12, and changes in the P53 gene are also associated with the occurrence of testicular tumors.
Testicular tumors are most common in people aged 15 to 35, usually manifested as painless masses in the scrotum on the affected side. About 20% of patients first experience scrotal pain, and more than 27% of patients experience local pain. Physical examination often shows enlargement of the testicle on the affected side, firm consistency, and loss of normal elasticity. Ultrasound examination is the preferred examination for testicular tumors, and routine examination should be performed for suspected cases. Chest X-ray examination is generally recommended as the most basic imaging examination by guidelines, and can detect lung metastases over 1cm. Abdominal and pelvic CT are the best examination methods for retroperitoneal lymph node metastasis, and can detect lymph nodes below 2cm. MRI and PET (Positron Emission Tomography) are not superior to CT in retroperitoneal lymph node metastasis and are not routine examination methods. Serum tumor markers mainly include alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH), among which LDH is mainly used for the examination of patients with metastatic testicular tumors. Placental alkaline phosphatase also has certain reference value for the staging of seminoma. Patients with no increase in tumor markers cannot be excluded from the possibility of having testicular tumors.
In recent years, there has been a significant change in the survival rate of testicular tumors, from 60% to 65% in the 1960s to over 90% in the 1990s. The treatment of testicular tumors has become a successful example of comprehensive treatment for solid tumors. The improvement in the cure rate of testicular tumors depends on correct clinical and pathological staging, the progress of imaging, the improvement of serum tumor marker detection, the advancement of surgical methods, the correct selection of chemotherapy regimens, and the progress of radiotherapy.